|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This mutation was un-detectable in pancreatic cancer tissue samples (n=65) and pancreatic cell line (n=10) DNA suggesting that pancreatic cancer progression is mainly dependent on the K-Ras mutation.
|
18783292 |
2008 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Importantly, T-UPSM demonstrated superior safety and antitumor efficacy over triptolide and T-NPSM in KRAS mutant pancreatic cancer mouse models.
|
30912923 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The activation of the K-ras gene at codon 12 is thought to be an early genetic event in the multistep pathogenesis of pancreatic cancer.
|
9586823 |
1998 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Through the PDC, we investigated the therapeutic impact of sorafenib alone, LEE001 alone and the combination of sorafenib and LEE001 in KRAS mutant PC.
|
30271501 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Efforts to model pancreatic cancer in mice have focused on mimicking genetic changes found in the human disease, particularly the activating KRAS mutations that occur in pancreatic tumors and their putative precursors, pancreatic intraepithelial neoplasia (PanIN).
|
19028876 |
2008 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activating K-Ras mutations occurs frequently in pancreatic cancers and is implicated in their development.
|
26904954 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In the current study, we apply systems biology approaches to enable a better understanding of the dynamics of the distinct metabolic alterations in KRAS-mediated pancreatic cancer, with the goal of impeding early cell proliferation by identifying the optimal metabolic enzymes to target.
|
28446878 |
2017 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By performing 70 screens in models of KRAS mutant colorectal, lung, ovarian, and pancreas cancers, we uncovered universal and tissue-specific sensitizing combinations involving inhibitors of cell cycle, metabolism, growth signaling, chromatin regulation, and transcription.
|
28746882 |
2017 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The current model of tumorigenesis, based on analyses of precursor lesions, termed pancreatic intraepithelial neoplasm (PanINs) lesions, makes two predictions: first, that pancreatic cancer develops through a particular sequence of genetic alterations (KRAS, followed by CDKN2A, then TP53 and SMAD4); and second, that the evolutionary trajectory of pancreatic cancer progression is gradual because each alteration is acquired independently.
|
27732578 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To determine whether detection of K-ras gene mutation in the histologically negative surgical margins of pancreatic cancer reflects unrecognised disease.
|
16682430 |
2006 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
|
29360815 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
With regard to pancreatic cancers, the authors' data confirm the very high frequency (88.6%) of Ki-ras gene mutations occurring at codon 12.
|
1741644 |
1991 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese.
|
2110130 |
1990 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
More than 90% of human pancreatic cancers are associated with oncogenic mutations of RAS, in particular K-RAS at codon 12.
|
16540233 |
2007 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
KRAS is the most commonly mutated oncogene in human cancer, with particularly high mutation frequencies in pancreatic cancers, colorectal cancers, and lung cancers [Ostrem, J. M., and Shokat, K. M. (2016) Nat.Rev.Drug Discovery 15, 771-785].
|
31042025 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our method for the detection of KRAS gene mutations may be useful to supplement histo/cytopathologic evaluations for pancreatic cancer, and is superior to serum CA19-9 in EUS-FNAB histo/cytopathology-indeterminate patients.
|
21876563 |
2011 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis.
|
19533561 |
2009 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
As KRAS mutation is prevalent in pancreatic cancer, the efficacy of these ligands against human pancreatic ductal carcinoma cell line PANC-1 and MiaPaCa2 were examined.
|
30223034 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The authors aimed to select discriminant methylated genes and to assess accuracy of these and mutant KRAS in stool to detect PanC.
|
22083596 |
2012 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Detection of KRAS or p53 mutation in plasma is not an effective screening tool for pancreatic cancer because accumulation of multiple mutations is required for malignant transformation in the pancreas.
|
29303908 |
2018 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.
|
31406261 |
2019 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
|
27517152 |
2016 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Somatic activating mutations at codon 12 of the K-ras gene are present in the majority of exocrine pancreatic cancers and occur early in tumorgenesis.
|
10548352 |
1999 |
|
Malignant neoplasm of pancreas
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we first observed that low FBW7 expression correlated significantly with ERK activation in pancreatic cancer clinical samples, primarily due to KRAS mutations in pancreatic cancer.
|
25753158 |
2015 |